Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

被引:0
作者
Vanille Laurent
Clémentine Fronteau
Chloé Antier
Pascale Dupuis
Benoit Tessoulin
Thomas Gastinne
Béatrice Mahé
Nicolas Blin
Viviane Dubruille
Anne Lok
Patrice Chevallier
Thierry Guillaume
Alice Garnier
Pierre Peterlin
Amandine Le Bourgeois
Sophie Vantyghem
Mourad Tiab
Pascal Godmer
Sophie Sadot
Marion Loirat
Adrien Trebouet
Nicolas Cormier
Steven Le Gouill
Philippe Moreau
Cyrille Touzeau
机构
[1] Pharmacie Clinique Oncologique,CRCINA, INSERM, CNRS
[2] Hotel Dieu,undefined
[3] Service d’Hématologie Clinique,undefined
[4] Hotel Dieu,undefined
[5] Etablissement Français du Sang,undefined
[6] Université de Nantes,undefined
[7] Faculté de Médecine,undefined
[8] Service d’Hématologie Clinique,undefined
[9] Centre Hospitalier Departemental,undefined
[10] Service d’Hématologie Clinique,undefined
[11] Centre Hospitalier,undefined
[12] Hôpital Privé Le Confluent,undefined
[13] Service d’Hématologie Clinique,undefined
[14] Centre Hospitalier,undefined
[15] Service d’Hématologie Clinique,undefined
[16] Centre Hospitalier,undefined
[17] Université de Nantes,undefined
[18] Site de Recherche Intégrée sur le Cancer (SIRIC),undefined
[19] ILIAD,undefined
[20] Université de Nantes,undefined
来源
Bone Marrow Transplantation | 2021年 / 56卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Triplet-drug regimen bortezomib–thalidomide–dexamethasone (VTD) and bortezomib–lenalidomide–dexamethasone (VRD) are considered as standard of care induction prior autologous stem-cell transplantation (ASCT) in myeloma. In addition to improve response rate, induction therapy should preserve an adequate stem-cell collection. In the present retrospective study, we analyzed stem-cell collection in 325 newly diagnosed myeloma patients who received either VTD or VRD induction before ASCT. Stem-cell mobilization consisted of intravenous cyclophosphamide plus G-CSF. Plerixafor was administered preemptively to rescue mobilization. In comparison with VTD, VRD induction was associated with a more frequent use of plerixafor (19.3% versus 5.4%, p = 0.004) and with an increased number of apheresis to reach adequate collection (>2 apheresis required in 42.3% versus 30.2%, p = 0.05). Moreover, more patients experienced collection failure in the VRD group (6% versus 1.8%, p = 0.004). The median number of CD34-positive cells (×106/kg) was lower in the VRD group: 8.5 versus 9.3 (p = 0.05) in the VTD group. The vast majority of patients underwent ASCT (93% versus 98%, in VRD and VTD group, respectively). These data highlight the need of optimal stem-cell collection strategy, especially in the context of tandem transplantation and incorporation of anti-CD38 monoclonal antibody into induction.
引用
收藏
页码:395 / 399
页数:4
相关论文
共 122 条
[1]  
Attal M(2017)Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma N Engl J Med 376 1311-20
[2]  
Lauwers-Cances V(2020)Newly diagnosed myeloma in 2020 Am Soc Clin Oncol Educ Book 40 1-15
[3]  
Hulin C(2012)Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 1589-96
[4]  
Leleu X(2016)VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Blood 127 2569-74
[5]  
Caillot D(2017)Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 28 iv52-61
[6]  
Escoffre M(2014)International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 e538-548
[7]  
Moreau P(1995)An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 86 3961-9
[8]  
Touzeau C(2009)Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma Bone Marrow Transplant 43 619-25
[9]  
Vij R(2009)International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Leukemia 23 1904-12
[10]  
Goldsmith SR(2009)Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma Blood 113 5720-6